线粒体靶向硫化氢供体AP39在失血性休克合并钝性胸部创伤小鼠模型中的作用
该研究在小鼠钝性胸部创伤(TxT)联合失血性休克(HS)模型中,于复苏阶段静脉推注AP39 100或10 nmol/kg或溶剂对照,随后回输 shed blood、液体复苏并使用去甲肾上腺素。高剂量AP39减轻全身炎症并降低肺组织iNOS和IκBα表达,但在TxT+HS组中高剂量AP39组平均动脉压最低、去甲肾上腺素需求最高、死亡率更高;低剂量AP39对血流动力学无影响,去甲肾上腺素需求和死亡率不变。作者结论认为AP39是全身抗炎剂,但在该创伤合并失血性休克模型中,由于其强效血管舒张特性,可能存在狭窄的剂量和治疗时间窗,可能加重或导致循环休克相关低血压。
要点
- 在TxT+HS小鼠中,高剂量AP39(100 nmol/kg静脉推注)组平均动脉压最低、去甲肾上腺素需求最高、死亡率更高。
- 低剂量AP39(10 nmol/kg静脉推注)对血流动力学无影响,去甲肾上腺素需求和死亡率与对照无差异。
- 高剂量AP39减轻全身炎症并降低肺组织iNOS和IκBα表达。
- 作者认为AP39的强效血管舒张特性可能导致狭窄的剂量和治疗时间窗,可能加重循环休克相关低血压。
适用人群与场景
- 小鼠模型:爆炸波诱导的钝性胸部创伤(TxT)或假手术,随后进行1小时失血和4小时复苏。
处置流程与药物剂量
- 麻醉并置管小鼠在失血1小时后进行4小时复苏,复苏包括静脉推注AP39 100或10 nmol/kg或溶剂、回输失血、液体复苏和去甲肾上腺素。
研究设计与关键结果
- 研究类型:小鼠模型研究;人群:爆炸波诱导TxT或假手术后接受1小时失血和4小时复苏的小鼠;干预:复苏时静脉推注AP39 100或10 nmol/kg或溶剂;主要结果:高剂量AP39减轻全身炎症并降低肺组织iNOS和IκBα表达;在TxT+HS组中,高剂量AP39组平均动脉压最低、去甲肾上腺素需求最高、死亡率更高;低剂量AP39对血流动力学无影响,去甲肾上腺素需求和死亡率不变。
证据类型、等级与局限
- 证据类型:动物实验(小鼠模型);局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在创伤合并失血性休克模型中,AP39由于其强效血管舒张特性,可能存在狭窄的剂量和治疗时间窗,可能加重或导致循环休克相关低血压。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Hemorrhagic shock (HS) accounts for 30% to 40% of trauma-induced mortality, which is due to multi-organ-failure subsequent to systemic hyper-inflammation, triggered by hypoxemia and tissue ischemia. The slow-releasing, mitochondria-targeted H2S donor AP39 exerted beneficial effects in several models of ischemia-reperfusion injury and acute inflammation. Therefore, we tested the effects of AP39-treatment in a murine model of combined blunt chest trauma (TxT) and HS with subsequent resuscitation.
METHODS: After blast wave-induced TxT or sham procedure, anesthetized and instrumented mice underwent 1 h of hemorrhage followed by 4 h of resuscitation comprising an i.v. bolus injection of 100 or 10 nmol kg AP39 or vehicle, retransfusion of shed blood, fluid resuscitation, and norepinephrine. Lung mechanics and gas exchange were assessed together with hemodynamics, metabolism, and acid-base status. Blood and tissue samples were analyzed for cytokine and chemokine levels, western blot, immunohistochemistry, mitochondrial oxygen consumption (JO2), and histological changes.
RESULTS: High dose AP39 attenuated systemic inflammation and reduced the expression of inducible nitric oxide synthase (iNOS) and IκBα expression in lung tissue. In the combined trauma group (TxT + HS), animals treated with high dose AP39 presented with the lowest mean arterial pressure and thus highest norepinephrine requirements and higher mortality. Low dose AP39 had no effects on hemodynamics, leading to unchanged norepinephrine requirements and mortality rates.
CONCLUSION: AP39 is a systemic anti-inflammatory agent. In our model of trauma with HS, there may be a narrow dosing and timing window due to its potent vasodilatory properties, which might result in or contribute to aggravation of circulatory shock-related hypotension.
参考来源
- Wepler M, Merz T, Wachter U, et al. The Mitochondria-Targeted H2S-Donor AP39 in a Murine Model of Combined Hemorrhagic Shock and Blunt Chest Trauma. Shock. 2019. PMID: 29927788. doi:10.1097/SHK.0000000000001210
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。